GlobeNewswire•Jun 1, 2026TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ImmunologyTGTX3.21%